Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trial

Abstract Background The phase 4 RESOLUTION trial showed that the first 12 weeks of treatment with eptinezumab, an anti-calcitonin gene-related peptide monoclonal antibody, reduced migraine frequency, severity, and disease burden, and improved quality of life (QOL) versus placebo in participants with...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Henrik W. Schytz, Rigmor H. Jensen, Christofer Lundqvist, Cristina Tassorelli, Fabrizio Vernieri, Michel Lantéri-Minet, Gisela M. Terwindt, Andrew Blumenfeld, Stewart J. Tepper, Mette Krog Josiassen, Gary Jansson, Anders Ettrup, Aurélia Mittoux, Richard B. Lipton
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMC 2026-06-01
سلاسل:	The Journal of Headache and Pain
الموضوعات:	Eptinezumab Patient education Patient-reported outcomes Chronic migraine Medication overuse headache Sustained response
الوصول للمادة أونلاين:	https://doi.org/10.1186/s10194-026-02423-x
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!